Title: Profile of Multidrug Resistant Acinetobacter Baumannii Infections among Hospitalized Patients
Authors: Anandhalakshmi Subramaniyan, Shashikala Nair, Noyal Maria Joseph, Reba Kanungo
DOI: https://dx.doi.org/10.18535/jmscr/v5i6.51
Abstract
Background: Infections by Acinetobacter baumanniiis posing serious healthcare-associated infections [HAIs] and the incidence is increasing, with many strains now being multidrug resistant [MDR]. MDR Acinetobacter baumannii confer a high risk of morbidity and mortality to hospitalized patients.
Aim: This study aimed to describe some of the common risk factors seen among hospitalized patients with Acinetobacter infection. Materials and methods: Acinetobacter baumannii isolates from invasive infection sites, numbering 120 were analysed. Clinical details and risk factors were documented in selected inpatients during the study period.
Results: Multidrug resistant [MDR] strains were 87% among all the isolates. Resistant to meropenem and imipenem were 75% and 62% respectively. The major risk factors associated with acquisition of MDR A.baumannii infection among the patients were hospital stay of more than 2 weeks [74.10%], followed by stay in ICU [72.50%], presence of indwelling intravascular device[69.10 %,] and mechanical ventilation [52.50%]. Positive blood culture for A.baumannii was associated with a mortality rate of 85%, with a confidence interval of [CI=82%-88%].
Conclusion: Significant risk factors were prolonged hospital stay, intravenous devices and mechanical ventilation. Further development of A.baumannii bacteremia is associated with a high mortality rate. Therefore to constrain the infection rate, both antibiotic policies and infection control policies have to be strictly followed.
Keywords: Acinetobacter, multidrug resistance, risk factors.
References
1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews 2008;21[3]:538-82.
2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nature Reviews Microbiology 2007;5[12]:939-51.
3. Villar M, Cano MaE, Gato E, Garnacho-Montero J, Cisneros JM, de Alegr+¡a CRz, et al. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: A reappraisal. Medicine 2014;93[5]:202-10.
4. Ozgur ES, Horasan ES, Karaca K, Ers+Âz G+, At-¦+SN, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control 2014;42[2]:206-8.
5. Wayne PA. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing 2010;17.
6. Heritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49[10]:4174-9.
7. Cerqueira GM, Peleg AY. Insights into Acinetobacter baumannii pathogenicity. IUBMB life 2011;63[12]:1055-60.
8. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clinical infectious diseases 2006;42[5]:692-9.
9. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. Journal of Hospital Infection 2007;65[3]:204-11.
10. Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical infectious diseases 2008;46[8]:1254-63.
11. Villar M, Cano MaE, Gato E, Garnacho-Montero J, Cisneros JM, de Alegr+¡a CRz, et al. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: A reappraisal. Medicine 2014;93[5]:202-10.
12. Rahbar M, Mehrgan H, Aliakbari NH. Prevalence of antibiotic-resistant Acinetobacter baumannii in a 1000-bed tertiary care hospital in Tehran, Iran. Indian Journal of Pathology and Microbiology 2010;53[2]:290.
13. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. The Journal of Infection in Developing Countries 2009;3[05]:335-41.
14. Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY, et al. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC infectious diseases 2010;10[1]:228.
15. Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, et al. Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PloS one 2012;7[5]:e37788.
16. Cisneros JM R-BJF-CFRAVJPAM-MLBGPJ. Riskfactors for the acquisition of imipenem resistant Acinetobacter baumannii in Spain: a nationwide study. Clinical Microbiology and Infection 2005;11[11]:874-9.
17. Mera RM, Miller LA, mrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002Çô2008: increase of carbapenem-associated multiclass resistance in the United States. Microbial Drug Resistance 2010;16[3]:209-15.
18. Gales AC, Jones RN, SaderHlS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program [2006Çô09]. Journal of Antimicrobial Chemotherapy 2011;66[9]:2070-4.
19. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acineto-bacter species and Stenotrophomona-smaltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program [1997Çô1999]. Clinical infectious diseases 2001;32[Supplement 2]:S104-S113.
20. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Archives of internal medicine 2002;162[13]:1515-20.
21. Centers for Disease Control and Prevention. National nosocomial infections surveillance [NNIS] report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance [NNIS] system. Am J Infect Control 1996;24:380-8.
22. Corbella X, Montero A, Pujol M, Dom+¡nguez MA, Ayats J, Argerich MJ, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistantAcinetobacterbaumannii. Journal of clinical microbiology 2000;38[11]:4086-95.
23. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Archives of internal medicine 2002;162[13]:1515-20.